iAnthus Capital HoldingsFRA:2IA -50.00% Pretax Margin % is -21.83% as of Mar. 2026. The stock has 4 warning signs investors should review. Among 952 Drug Manufacturers companies, iAnthus Capital Holdings ranks worse than 83.61% on this metric.
The historical rank and industry rank for iAnthus Capital Holdings's Pretax Margin % or its related term are showing as below:
FRA:2IA'
s Pretax Margin % Range Over the Past 10 Years
Min: -1821.66 Med: -194.32 Max: -15.11
Current: -28.42
FRA:2IA's Pretax Margin % is ranked worse than 83.61% of 952
companies
in the Drug Manufacturers industry
Industry Median: 7.295
vs FRA:2IA: -28.42
iAnthus Capital Holdings (FRA:2IA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
iAnthus Capital Holdings Pretax Margin % Related Terms
iAnthus Capital Holdings Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, iAnthus Capital Holdings's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iAnthus Capital Holdings Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iAnthus Capital Holdings's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where iAnthus Capital Holdings's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iAnthus Capital Holdings (FRA:2IA) has a Pretax Margin % of -21.83% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on iAnthus Capital Holdings and its competitors. According to the industry distribution chart, iAnthus Capital Holdings ranks #796 out of 952 companies in the Drug Manufacturers industry, placing it in the top 83.6%.
Is iAnthus Capital Holdings' Pretax Margin % too high?
iAnthus Capital Holdings' current Pretax Margin % is -21.83%. Based on the distribution chart, iAnthus Capital Holdings ranks #796 out of 952 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does iAnthus Capital Holdings' Pretax Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, iAnthus Capital Holdings ranks #796 out of 952 companies for Pretax Margin %. This places iAnthus Capital Holdings in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on iAnthus Capital Holdings and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iAnthus Capital Holdings's current Pretax Margin % is -21.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iAnthus Capital Holdings stock overvalued right now?
iAnthus Capital Holdings (FRA:2IA) has a current Pretax Margin % of -21.83%. The current Pretax Margin % is -21.83%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For iAnthus Capital Holdings (FRA:2IA), the current Pretax Margin % is -21.83% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
iAnthus Capital Holdings Inc is a vertically-integrated, multi-state owner and operator of licensed cannabis cultivation, processing, and dispensary facilities and a developer, producer, and distributor of branded cannabis products in the United States. Its Cannabis product offerings include flower and trim, products containing cannabis flower and trim (such as packaged flower and pre-rolls), cannabis infused products (such as topical creams and edibles), and products containing cannabis extracts (such as vape cartridges, concentrates, live resins, wax products, oils, and tinctures). The company's reportable operating segments are the Eastern Region, which generates the maximum revenue, and the Western Region.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2IA has been successfully added to your 